AVEO Oncology (Formerly known as AVEO Pharmaceuticals, Inc.) Reports 2012 Financial Results and Highlights Recent Accomplishments

Published: Feb 13, 2013

AVEO Oncology (NASDAQ: AVEO) today reported consolidated 2012 financial results and reviewed key recent accomplishments.

“We continue to make significant progress with tivozanib, including reporting the final overall survival results from TIVO-1, receiving the FDA’s acceptance of the NDA submission and expanding tivozanib clinical development into patients with triple negative breast cancer,” said Tuan Ha-Ngoc, president and chief executive officer of AVEO.

Back to news